Brez internetne povezave — prikazana je shranjena različica strani.

Silence Therapeut…

USUSD
← Na Filter Delnic

Silence Therapeutics PLC (US:SLNCF) — Biotechnology: Pharmaceutical Preparations. Število borz, na katerih se trgujejo delnice družbe: 1. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.

O Podjetju

Spletna Stran
silence-therapeutics.com
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Sedež
LONDON, United Kingdom
Izvršni Direktor
Iain Gladstone Ross
Zaposleni
88
Delnice v Obtoku
141.74 mio. na dan 2026-07-31
Prosto Prenosljive Delnice
37.84 mio.
Tržna Kapitalizacija
665.67 mio. USD
Notranje Osebe
7.97%
Institucionalni Vlagatelji
39.68%
Panoga (SIC)
Pharmaceutical Preparations
FCF
−42.3 mio. USD
Dolg
?
Dobiček in FCF — za 12 mesecev do 30.06.2026 (najnovejše poročilo podjetja).
NAV
0.27 USD · P/NAV 14.2
Datum Bilance Stanja30.06.2026
Sredstva106 mio. USD
− Obveznosti67.9 mio. USD
= NAV (lastniški delež delničarjev podjetja)38.5 mio. USD
− Dobro Ime10.3 mio. USD
= Opredmetena NAV28.1 mio. USD
Delnice141 739 180
NAV na Delnico0.27 USD
Otipljiv NAV na Delnico0.20 USD
Cena Delnice (SLNCF)3.8500 USD
P/NAV14.18
Zgodovina NAV
Datum Bilance StanjaNAVNAV na Delnico
30.06.202638.5 mio. USD0.27 USD
31.03.202649.4 mio. USD0.35 USD
31.12.202562.3 mio. USD0.44 USD
30.09.202574.1 mio. USD0.52 USD
30.06.202594.2 mio. USD0.66 USD
31.03.2025113 mio. USD0.80 USD
31.12.2024134 mio. USD0.95 USD
30.09.2024127 mio. USD0.89 USD
Opis

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

oglas

Borze in Oznake

BorzaOznakaValutaCenaVrsta
US USA StocksSLNCFUSD3.85 -3.75%navadne delnice

Cena v 3 Mesecih

US:SLNCF · USD
dan rasti dan padcaPremaknite miško / tapnite dan — otvoritvena, zaključna, najvišja in najnižja cena

Največji Imetniki

ImetnikDeležDelniceDatum Poročila
Siren, L.L.C.5.5%3.31 mio.2026-06-30
TCG Crossover Management…5.04%3.03 mio.2026-06-30
Redmile Group, LLC3.6%2.16 mio.2026-06-30
Nantahala Capital Manage…2.24%1.35 mio.2026-06-30
Citadel Advisors Llc2.21%1.33 mio.2026-06-30
Nextech Invest, Ltd.1.58%952 4002026-06-30
Millennium Management Ll…1.51%909 2792026-06-30
Ikarian Capital, LLC1.38%830 7842026-06-30
Tetragon Partners GP Ltd…1.27%764 2562026-06-30
Soleus Capital Managemen…1.05%630 0002026-06-30
Fidelity Advisor Series…0.8%482 0882026-07-31
iShares Trust-iShares Bi…0.39%234 0092026-08-31
ALGER FUNDS-Alger Small…0.18%105 6792026-07-31
Fidelity Select Portfoli…0.17%103 9122026-07-31
ALGER INSTITUTIONAL FUND…0.07%41 2922026-07-31
Fidelity Concord Street…0.05%29 5382026-07-31
SPDR INDEX SHARES Fd.S-S…0.02%9 5322026-06-30
Trust for Professional M…0.01%8 6952026-05-31
Steward Funds Inc-Stewar…0.01%5 8002026-07-31
Invesco Exchange-Traded…0%2 9182026-08-31